Replies to post #11651 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: NovoSeven for ICH

I don’t think NVO will run the requested study. They’ve made their decision to abandon the ICH indication (#msg-17380185); from a business standpoint, there’s no compelling reason for them to reconsider.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”